TABLE 1.
Clinical and biological characteristics of HIV-infected patients and HIV-uninfected controls
| HIV-Infected Patients | ||||
| HIV-Uninfected Controls (n = 200) | Before HAART (n = 231) | Before HAART (n = 41) | After HAART (n = 41) | |
| Clinical parameters | ||||
| Age, years | 43.3 ± 12.8 | 37.2 ± 9.4a | 38.3 ± 11.5 | |
| Gender, M/F | 147/53 | 177/54 | 36/5 | |
| BMI, kg/m2 | 27.1 ± 4.7 | 23.6 ± 3.4a | 23.8 ± 3.8 | 24.1 ± 4.3 |
| Plasma parameters (mg/dl) | ||||
| TC | 203.2 ± 43.9 | 173.0 ± 42.3a | 161.4 ± 25.3 | 198.6 ± 34.5c |
| TGs | 110.5 ± 49.5 | 104.1 ± 66.4 | 112.7 ± 39.2 | 116.3 ± 44.7 |
| LDL-C | 130.7 ± 41.2 | 108.2 ± 35.8a | 103.7 ± 28.6 | 126.2 ± 35.1c |
| HDL-C | 50.3 ± 16.4 | 44.2 ± 13.8a | 35.2 ± 8.1 | 49.1 ± 12.6c |
| apoB | 102.6 ± 27.3 | 81.8 ± 23.4a | 77.9 ± 12.7 | 85.9 ± 19.2c |
| apoAI | 144.4 ± 32.7 | 108.3 ± 23.4a | 97.2 ± 17.1 | 126.0 ± 21.9c |
| Endogenous plasma CETP activity (%) | 29.7 ± 7.2 | 27.6 ± 7.4b | 26.9 ± 6.5 | 29.0 ± 6.7d |
a
P < 0.0001 versus HIV-uninfected controls.
b
P < 0.05 versus HIV-uninfected controls after adjustment for LDL-C, HDL-C, TG, age, and BMI.
c
P < 0.05 versus HIV-infected patients before HAART (n = 41).
d
P < 0.05 versus HIV-infected patients before HAART (n = 41) and after adjustment for LDL-C, HDL-C, TG, age, and BMI.